Vericel (NASDAQ:VCEL – Get Rating) was downgraded by equities researchers at BTIG Research from a “buy” rating to a “neutral” rating in a research note issued on Wednesday, MarketBeat Ratings reports.
Other analysts have also recently issued research reports about the company. StockNews.com assumed coverage on Vericel in a research report on Wednesday, October 12th. They set a “sell” rating on the stock. Truist Financial cut Vericel from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Stephens initiated coverage on Vericel in a research report on Thursday, October 13th. They set an “overweight” rating and a $40.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $37.40.
Vericel Trading Up 27.0 %
Shares of NASDAQ VCEL opened at $22.41 on Wednesday. The stock has a market capitalization of $1.06 billion, a PE ratio of -62.25 and a beta of 1.99. The stock’s fifty day simple moving average is $24.51 and its two-hundred day simple moving average is $26.57. Vericel has a 12-month low of $17.30 and a 12-month high of $46.30.
Hedge Funds Weigh In On Vericel
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.
- Get a free copy of the StockNews.com research report on Vericel (VCEL)
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
- Coupang Stock And Why You Should Care
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.